Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches (Q37489947)

20 August 2017

1 reference

title

Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches (English)

1 reference

20 August 2017

0 references

Francis Dumont

1

1 reference

20 August 2017

Anais Altmeyer

series ordinal

2

1 reference

20 August 2017

Pierre Bischoff

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

1 reference

20 August 2017

19

1 reference

20 August 2017

6

1 reference

20 August 2017

775-799

1 reference

Chemical radiosensitizers for use in radiotherapy

20 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Current concepts for the combined treatment modality of ionizing radiation with anticancer agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Radiation-induced DNA damage responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Targeted cancer therapies based on the inhibition of DNA strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

DNA repair pathways as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Regulation of the cellular DNA double-strand break response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Small molecules targeting p53 to improve antitumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Repair of radiation induced DNA double strand breaks by backup NHEJ is enhanced in G2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Effect of 6(5H)-phenanthridinone, a poly (ADP-ribose)polymerase inhibitor, and ionizing radiation on the growth of cultured lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Rational bases for the development of EGFR inhibitors for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Radiation-induced cell signaling: inside-out and outside-in

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Radiation-induced EGFR-signaling and control of DNA-damage repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

NF-kappa B-mediated adaptive resistance to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Advances in targeting IKK and IKK-related kinases for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Targeted manipulation of apoptosis in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Sensitization of pancreatic carcinoma cells for γ-irradiation-induced apoptosis by XIAP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Survivin, cancer networks and pathway-directed drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Inhibition of histone deacetylation: a strategy for tumor radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

The Hsp90 molecular chaperone: an open and shut case for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Inhibition of Hsp90: a multitarget approach to radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Discovery and development of heat shock protein 90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

21 January 2018

Vascular damaging agents

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Molecular mechanisms and therapeutic development of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Antiangiogenics and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Vascular endothelial growth factor (VEGF) signaling in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Hypoxia: a key regulator of angiogenesis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Alpha-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3'-sulfoquinovosyl-1'-monoacylglycerol, targeting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Design of antiangiogenic hypoxic cell radiosensitizers: 2-nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

Recent insights into the biological action of heavy-ion radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967666

10.1517/13543770902967666

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference